-
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
(Hinzugefügt: 13.05.2022 um 07:56 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00519-0/fulltext
-
Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE – Coalition V): A double-blind, multicentre, randomised, controlled trial
(Hinzugefügt: 03.04.2022 um 17:56 Uhr)
https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00060-6/fulltext
-
Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients
(Hinzugefügt: 04.10.2021 um 09:19 Uhr)
https://rcm.imrpress.com/EN/10.31083/j.rcm2203116
-
Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial (HERO-HCQ)
(Hinzugefügt: 28.08.2021 um 13:48 Uhr)
https://www.medrxiv.org/content/10.1101/2021.08.19.21262275v1
-
Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19
(Hinzugefügt: 24.04.2021 um 05:46 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779044
-
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
(Hinzugefügt: 17.04.2021 um 10:08 Uhr)
https://www.nature.com/articles/s41467-021-22446-z
-
Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2
(Hinzugefügt: 22.01.2021 um 21:44 Uhr)
https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009212
-
Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19
(Hinzugefügt: 17.01.2021 um 17:56 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779282/
-
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study
(Hinzugefügt: 16.01.2021 um 08:33 Uhr)
https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-05773-w
-
Henry Ford study on hydroxychloroquine for COVID quietly shut down
(Hinzugefügt: 12.01.2021 um 07:38 Uhr)
https://www.bridgemi.com/michigan-health-watch/henry-ford-study-hydroxychloroquine-covid-quietly-shut-down
-
Comparing ICU Admission Rates of Mild/Moderate COVID-19 Patients Treated with Hydroxychloroquine, Favipiravir, and Hydroxychloroquine plus Favipiravir
(Hinzugefügt: 30.12.2020 um 07:57 Uhr)
https://www.sciencedirect.com/science/article/pii/S1876034120307735
-
Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin
(Hinzugefügt: 14.12.2020 um 18:38 Uhr)
https://www.sciencedirect.com/science/article/pii/S1477893920304518
-
Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: A pilot observational study
(Hinzugefügt: 13.12.2020 um 20:47 Uhr)
https://www.sciencedirect.com/science/article/pii/S0735675720311335
-
Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: prospective, non-randomized trial
(Hinzugefügt: 10.12.2020 um 09:45 Uhr)
https://www.sciencedirect.com/science/article/pii/S0213005X20304134
-
Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection
(Hinzugefügt: 09.12.2020 um 00:19 Uhr)
https://www.acpjournals.org/doi/full/10.7326/M20-6519
-
HCQ is effective for COVID-19 when used early: analysis of 152 studies
(Hinzugefügt: 02.12.2020 um 22:03 Uhr)
https://hcqmeta.com/
-
Hydroxychloroquin und Chloroquin: Arzneimittelbehörden warnen vor psychiatrischen Nebenwirkungen
(Hinzugefügt: 01.12.2020 um 08:26 Uhr)
https://www.aerzteblatt.de/nachrichten/118878/Hydroxychloroquin-und-Chloroquin-Arzneimittelbehoerden-warnen-vor-psychiatrischen-Nebenwirkungen
-
A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 List of authors.
(Hinzugefügt: 26.11.2020 um 08:47 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2021801
-
Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19
(Hinzugefügt: 22.11.2020 um 09:31 Uhr)
https://www.sciencedirect.com/science/article/pii/S2589537020303898
-
Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19
(Hinzugefügt: 11.11.2020 um 08:37 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2772922
-
Misguided Use of Hydroxychloroquine for COVID-19
(Hinzugefügt: 11.11.2020 um 08:00 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2772921
-
Hydroxychloroquine does not benefit adults hospitalized with COVID-19
(Hinzugefügt: 10.11.2020 um 08:21 Uhr)
https://www.nih.gov/news-events/news-releases/hydroxychloroquine-does-not-benefit-adults-hospitalized-covid-19
-
Post Exposure Prophylaxis
(Hinzugefügt: 07.11.2020 um 08:26 Uhr)
https://www.sciencedirect.com/science/article/pii/S0924857920304350
-
pre-exposure use of hydroxychloroquine
(Hinzugefügt: 06.11.2020 um 07:51 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30378-7/fulltext
-
Low dose hydroxychloroquine is associated with lower mortality in COVID-19:
(Hinzugefügt: 05.11.2020 um 12:28 Uhr)
https://www.medrxiv.org/content/10.1101/2020.11.01.20223958v1
-
SOLIDARITY data
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://blogs.sciencemag.org/pipeline/archives/2020/10/16/the-solidarity-data
-
Covid-19 Outpatients
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.sciencedirect.com/science/article/pii/S1477893920304026
-
Hydrochloroquine
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.nature.com/articles/s41587-020-0686-x
-
SOLIDARITY trial
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1